{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"10.3","value":"4.9"}]}],"title":"Cardiac toxicities"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"10.3","value":"4.9"}]}],"title":"Treatment-related deaths"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"0","value":"0"}]}],"title":"Sinusoidal Obstruction Syndrome"}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"}],"units":"Participants"}],"description":"Percentage of participants with Grade 4 cardiac toxicities, Grade 4 Sinusoidal Obstruction Syndrome (SOS), and treatment-related deaths determined using CTCAE v4.","dispersionType":"95% Confidence Interval","groups":[{"description":"Combined UH-1, UH-2, and Window/UH-1 for revised-UH toxicity monitoring","id":"OG000","title":"Combined UH-2, UH-1, Window/UH-1"}],"paramType":"NUMBER","populationDescription":"Eligible patients treated after Amendment 3A for arms UH-1, UH-2, and Window/UH-1.","reportingStatus":"POSTED","timeFrame":"Up to 4 years","title":"Toxicity Rate","type":"PRIMARY","unitOfMeasure":"Percentage of patients"}